Riskified (RSKD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Chett Mandel - Head, Investor RelationsEido Gal - Co-Founder and CEOAglika Dotcheva - Chief Financial OfficerConnor Passarella - Equity Research AssociateRyan Tomasello - Managing DirectorTimothy Chiodo - Managing Director Conference Call Participants Cristopher Kennedy - Research Analyst, Financial Services and TechnologyClark Wright - AVP - Research Analyst Operator Good day, and thank you for standing by. Welcome to the ...

Financial Data and Key Metrics Changes - Celebrite achieved a 23% year-on-year growth in Annual Recurring Revenue (ARR), reaching $408 million [26] - Adjusted EBITDA grew by 34% year-on-year, resulting in a 22% margin [8] - First quarter revenue was $107.5 million, a 20% increase from the previous year, primarily driven by a 21% growth in subscription revenue [30] - Non-GAAP net income was $26.2 million, with diluted non-GAAP EPS growing by 25% [32] Business Line Data and Key Metrics Changes - The Insights product family drove the majority of net ARR expansion, with a significant uplift from transitioning legacy digital forensics licenses [28] - Guardian's ARR growth rate exceeded 100% for the third consecutive quarter, indicating strong adoption [30] - Pathfinder is growing in line with the core business, with new enhancements expected to change its adoption trajectory [78] Market Data and Key Metrics Changes - The Americas region grew by 27%, with strong performance in state and local government and Latin America [27] - EMEA experienced a 15% growth, while Asia Pacific saw a 28% increase in ARR [27] - The U.S. Federal segment showed modest shortfalls, impacting overall performance [10] Company Strategy and Development Direction - Celebrite is focused on growth while managing spending to support bottom-line objectives, with a commitment to expanding its product offerings in AI and cloud technologies [24][8] - The company is doubling down on the intelligence and defense sectors, responding to increased demand driven by geopolitical factors [14][75] - Celebrite is actively pursuing FedRAMP authorization to enhance its federal business opportunities [59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of 2025, citing an expanding pipeline and the potential for recovery in federal spending [13][36] - The company remains cautious about the federal spending environment but sees opportunities for growth in intelligence and defense sectors [12][90] - Management highlighted the importance of their solutions in addressing rising crime rates and the sophistication of technology used in criminal activities [52] Other Important Information - Celebrite held its first user conference, attracting approximately 700 attendees from various agencies and enterprises [18] - The company is in the process of searching for a new CEO, ensuring that operations continue effectively during this transition [21] - Celebrite's cash and investments totaled $509.8 million, reflecting strong financial health [34] Q&A Session Summary Question: Is there any deterioration in the demand environment? - Management noted no material change in leadership decision-making, with optimism stemming from an uptick in pipeline opportunities [42][43] Question: What visibility is there regarding deal slippage? - Management indicated that while some deals are being deferred, the overall pipeline is improving, and they expect clarity post-Memorial Day [48][90] Question: Update on FedRAMP certification timing? - Management is targeting the end of Q3 for FedRAMP certification, pending sponsorship from federal agencies [59] Question: Insights on EMEA efforts? - Management emphasized the importance of global presence and commitment to the EMEA market, highlighting recent executive visits to strengthen relationships [66] Question: Why not embed more conservatism in the second half guidance? - Management expressed confidence in the pipeline and the necessity of their software, believing that demand will rebound in the second half [71][75] Question: Performance of the Pathfinder product? - Pathfinder is growing in line with the core business, with new enhancements expected to boost adoption [78] Question: Specific items in the Memorial Day budget? - Management identified several key programs related to security and crime prevention that are expected to be funded [85]

Alico (ALCO) Q2 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants John Mills - Managing PartnerJohn Kiernan - President and Chief Executive OfficerBrad Heine - CFOBrandon Rogers - Equity Research Associate Operator Morning, and welcome to Aleco's Second Quarter twenty twenty five Earnings Call. Currently, all participants are in a listen only mode. As a reminder, today's conference is being recorded. I would now like to turn the call over to your host, John Mills, Managing Partner at ICR. Joh ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $23 million, including net product revenues of $17.4 million, which is consistent with Q1 2024 and an increase from $16.4 million in Q4 2024 [5][16] - Net loss for Q1 2025 was $38.6 million, an improvement from a net loss of $46.6 million in Q1 2024, primarily due to higher license revenues and lower expenses [17] - Cash and cash equivalents as of March 31, 2025, were $194.7 million, down from $250.9 million at December 31, 2024, mainly due to net loss from operations and timing of cash receipts [17] Business Line Data and Key Metrics Changes - Milestone and royalty payments contributed an additional $5.6 million to total revenue for the quarter [6] - The LOTUS-seven study showed a 95.5% overall response rate and a 90.9% complete response rate in 22 efficacy evaluable patients [14] Market Data and Key Metrics Changes - The company is focusing on maintaining its position as a treatment option for third-line plus DLBCL patients, with ongoing trials showing promising data [5][9] - The competitive landscape is highlighted by the potential of ZYNLATA plus glufitamab to be a best-in-class combination in a highly competitive market [6][10] Company Strategy and Development Direction - The company aims to expand the use of ZYNLATA into earlier lines of therapy in DLBCL and indolent lymphomas, believing in the potential for significant patient reach and commercial opportunity [9][10] - Regulatory discussions are planned based on data from 100 patients, aligning with recent examples of bispecific combination therapies [10][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the cash runway extending into the second half of 2026, positioning the company to deliver on upcoming catalysts [20] - The management is encouraged by the promising data from ongoing trials and believes in multiple pathways to achieve peak revenue goals [22] Other Important Information - The LOTUS-five trial is on track to reach the pre-specified number of progression-free survival events by the end of 2025, with top-line data expected thereafter [7][19] - The company is engaged in discussions for potential research collaborations to advance its preclinical assets [8][19] Q&A Session Summary Question: Follow-up time for patients and CR conversion times - Management indicated that follow-up assessments are ongoing, with encouraging complete response rates serving as strong biomarkers for durability [24][27] Question: Competitive strategy and regulatory engagement - Management plans to engage with regulatory authorities after gathering data from approximately 100 patients, assessing the best path forward [29][47] Question: Expected patient numbers at upcoming conferences - Management confirmed that 40 patients have been enrolled, with additional patients expected to be presented at the EHA conference [33][34] Question: LOTUS-five trial data expectations - Management reiterated that the timing for top-line data from the LOTUS-five trial could be late 2025 or early 2026, depending on the number of PFS events [42][43] Question: Discontinuation of the ADCT-602 program - Management clarified that the discontinuation of the ADCT-602 program has minimal financial impact, allowing focus on other research programs [49][50]

Kornit Digital (KRNT) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Jared Maymon - Global Head of Investor RelationsRonen Samuel - CEOLauri Hanover - Chief Financial OfficerErik Woodring - Managing Director - Equity ResearchBrian Drab - Co-Group Head–IndustrialsTroy Jensen - Managing DirectorChris Grenga - Equity Research Associate Conference Call Participants Greg Palm - Senior Research AnalystChristopher Moore - Senior AnalystChris Reimer - Analyst Operator Greetings, and welcome to ...

ARS Pharmaceuticals (SPRY) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Justin Chakma - Chief Business OfficerRichard Lowenthal - Co Founder, President, CEO & DirectorEric Karas - Chief Commercial OfficerKathleen Scott - Chief Financial OfficerRyan Deschner - Vice President - Equity ResearchJosh Schimmer - Managing DirectorLouise Chen - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystLachlan Hanbury-Brown - Biotech Equity Res ...

Riskified (RSKD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Chett Mandel - Head, Investor RelationsEido Gal - Co-Founder and CEOAglika Dotcheva - Chief Financial OfficerConnor Passarella - Equity Research AssociateRyan Tomasello - Managing DirectorTimothy Chiodo - Managing Director Conference Call Participants Cristopher Kennedy - Research Analyst, Financial Services and TechnologyClark Wright - AVP - Research Analyst Operator Good day, and thank you for standing by. Welcome to the ...

PolyPid (PYPD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Brian Ritchie - Managing DirectorDikla Akselbrad - CEOOri Warshavsky - Chief Operating Officer - USJonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - Equity Research AnalystChase Knickerbocker - Senior Equity Research Analyst - HealthcareBoobalan Pachaiyappan - Managing Director, Senior Research Analyst Operator and thank you for standing by. Welcome to the Polypede First Quarter twenty twe ...

Financial Data and Key Metrics Changes - The company ended the quarter with approximately $8 million in cash, which is expected to sustain operations into the third quarter of 2025 [20] - A need to raise approximately $15 million to support operations into the first quarter of 2026 was highlighted [21] - The market capitalization has increased to over $14 million with 14.1 million shares outstanding [22] Business Line Data and Key Metrics Changes - The Phase III MIRACLE trial for Anamycin has officially started, with the first patient treated and 38 sites selected worldwide [5] - The company received complete sign-off from the European Medicines Agency (EMA) for all nine countries intended for the trial in the EU, marking a significant milestone [6] - The company is also working on WP1066, a lead STAT3 inhibitor, which is currently in an investigator-sponsored clinical trial [10] Market Data and Key Metrics Changes - The trading volume has been healthy, with a three-month average of nearly 6 million shares traded per day [22] - A spike in trading volume was noted with approximately 2.4 million shares traded following the EU news [22] Company Strategy and Development Direction - The company aims to position Anamycin as a potentially non-cardiotoxic anthracycline, which could disrupt the market for cancer treatments [24] - The focus is on achieving a complete remission rate of at least 17.5% in the MIRACLE trial to meet FDA approval requirements [18] - The company is also looking to harmonize US and EU trial protocols to streamline the study process [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts and the potential for significant market cap increases based on trial results [23] - The company believes it is well-positioned to achieve FDA approval based on its Phase II efficacy data, which outperforms existing treatments [25] - Management acknowledged the challenges of developing new formulations but remains optimistic about achieving targets by the end of the year [32] Other Important Information - The company announced additional patent protection extending into at least February 2040, enhancing the protection around its core asset [7] - The final data from the MD-107 clinical trial using Anamycin to treat advanced soft tissue sarcoma is expected to be announced soon [8] Q&A Session Summary Question: Does the statement about results being submitted as a substantial modification to the EMA have negative implications for the timeline of EU approval versus US? - Management does not expect significant delays, as the EMA requested additional GLP preclinical data, which can be produced in a timely manner [30] Question: How close is Emory to getting an optimum formulation for IV delivery? - Management believes they are in the implementation stage for a new formulation and expects to have updates by the end of the year [32] Question: Is the $3.5 million a fair run rate for R&D for the rest of the year? - Management indicated that R&D expenses will increase, especially as they head into 2026 with GLP and manufacturing expenses [34]

Gladstone Investment (GAIN) Q4 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants David Gladstone - Founder, Chairman & CEOMichael Licalsi - General Counsel & SecretaryDavid Dullum - PresidentTaylor Ritchie - CFOMickey Schleien - MD - Equity ResearchErik Zwick - Managing Director, Equity Research Operator and welcome to Gladstone Investment Corporation Fourth Quarter and Year End Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session w ...